NCT02819934View on ClinicalTrials.gov

A Phase I Study to Investigate the ADME of KD101

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 20, 2016

Primary Completion Date

June 6, 2016

Study Completion Date

December 15, 2018

Conditions
Obesity
Interventions
DRUG

KD101

after 10 min KD101 administered, 14C KD101 3.52ug/1ml administrated. both of them will be administrate for oral

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT02819934 - A Phase I Study to Investigate the ADME of KD101 | Biotech Hunter | Biotech Hunter